HELA‐Exos is specifically targeted to the tumour microenvironment and induces ICD by activating conventional type 1 dendritic cells (cDC1s) in TNBC cells, thereby enhancing CD8+ T cell responses against tumours [98]. This evidence concerns the gene CD8A and neoplasm.